🇯🇵·15h agoIndustry
U.S. FDA Approves INQOVI® in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapy
Publisher
O
Otsuka Holdings RSS
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on taiho.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Otsuka Holdings RSS
Scope: Industry
Related coverage
More related coverage
Eli Lilly News·4h ago
Lilly and UNICEF collaborate to give millions of children a healthier start
Chugai Pharmaceutical News·8h ago
ヒト化抗CD20モノクローナル抗体「ガザイバ」特発性ネフローゼ症候群に対して適応拡大申請
Chugai Pharmaceutical·8h ago
Filing of Humanized Anti-CD20 Monoclonal Antibody Gazyva for Additional Indication of Idiopathic Nephrotic Syndrome
Astellas Pharma·9h ago